Trans Genic Inc. (JP:2342)

:2342

2342

Trans Genic Inc.

RESEARCH TOOLSreports

Want to see JP:2342 full AI Analyst Report?

Trans Genic Inc. (2342) Price & Analysis

0 Followers

2342 Stock Chart & Stats

¥254.00

-¥3.00(-1.68%)

At close: Jan 08 4:00 PM EST

¥254.00

-¥3.00(-1.68%)

Day’s Range― - ―

52-Week Range¥150.00 - ¥487.00

Previous CloseN/A

Volume37.40K

Average Volume (3M)549.15K

Market Cap

¥4.18B

Enterprise Value¥4.08B

Total Cash (Recent Filing)¥2.30B

Total Debt (Recent Filing)¥2.85B

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-57.85

Shares Outstanding16,999,142

10 Day Avg. Volume1,508,680

30 Day Avg. Volume549,150

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)0.89

Price to Sales (P/S)0.32

P/FCF Ratio-100.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Niche Research Tools BusinessTrans Genic operates in a specialized life-sciences niche supplying genetically engineered animal models for drug discovery and biomedical research. This addresses durable demand from research institutions and pharma, creating technical barriers, repeat service needs, and sticky customer relationships over the medium term.

Serviceable Balance Sheet With Equity CushionModerate leverage and a sizable equity base provide solvency support and financial flexibility, reducing short-term bankruptcy risk. This cushion helps the company fund R&D and operational needs while pursuing stabilization, improving resilience during loss-making periods versus peers with weaker capitalization.

Operating Profitability Recovering In 2026The move back to positive EBIT/EBITDA in 2026 indicates management has begun to restore operating leverage or cut structural costs. If sustained, this demonstrates a pathway to cash-generative operations, enhancing funding options and reducing reliance on external capital over the coming quarters.

Bears Say

Persistent Negative Free Cash FlowSustained negative free cash flow since 2023 implies ongoing cash burn and a structural funding gap. This forces reliance on external financing or equity issuance, which can dilute shareholders and constrain long‑term R&D or capacity investments unless the company converts operating profits into consistent positive cash flow.

Highly Volatile ProfitabilityRecurring net losses and sharp swings in profitability reduce predictability of margins and earnings power. This volatility hampers long‑term planning, weakens creditor and supplier confidence, and raises the risk that recent operating gains will reverse, undermining durable improvements in cash generation.

Material Revenue Decline Raises Demand RiskA material top‑line decline in 2026 signals demand instability or loss of business, threatening the sustainability of margin recovery. Lower revenue reduces scale benefits, limits ability to absorb fixed costs, and challenges the durability of operational improvement absent a clear recovery in underlying demand.

2342 FAQ

What was Trans Genic Inc.’s price range in the past 12 months?

Trans Genic Inc. lowest stock price was ¥150.00 and its highest was ¥487.00 in the past 12 months.

What is Trans Genic Inc.’s market cap?

Trans Genic Inc.’s market cap is ¥4.18B.

When is Trans Genic Inc.’s upcoming earnings report date?

Trans Genic Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 83 days.

How were Trans Genic Inc.’s earnings last quarter?

Trans Genic Inc. released its earnings results on May 13, 2026. The company reported -¥6.32 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.32.

Is Trans Genic Inc. overvalued?

According to Wall Street analysts Trans Genic Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Trans Genic Inc. pay dividends?

Trans Genic Inc. pays a Annually dividend of ¥3 which represents an annual dividend yield of N/A. See more information on Trans Genic Inc. dividends here

What is Trans Genic Inc.’s EPS estimate?

Trans Genic Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Trans Genic Inc. have?

Trans Genic Inc. has 16,999,142 shares outstanding.

What happened to Trans Genic Inc.’s price movement after its last earnings report?

Trans Genic Inc. reported an EPS of -¥6.32 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.575%.

Which hedge fund is a major shareholder of Trans Genic Inc.?

Currently, no hedge funds are holding shares in JP:2342

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Trans Genic Inc.

Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.